At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALLR Allarity Therapeutics Inc
Market Closed 06-14 16:00:00 EDT
0.4549
-0.0129
-2.76%
盘后0.4500
-0.0049-1.08%
19:59 EDT
High0.4800
Low0.4380
Vol2.62M
Open0.4700
D1 Closing0.4678
Amplitude8.98%
Mkt Cap8.01M
Tradable Cap8.01M
Total Shares17.61M
T/O1.19M
T/O Rate14.91%
Tradable Shares17.61M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Allarity Therapeutics Signs New Management Services Agreement
Allarity Therapeutics Reports Clear Clinical Benefits From Phase 2 Trial; Improves Cash Balance Of $14M And Equity Balances Of $15M; Withdraws From S-1
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.